· Selected as a presenterfor the fifth consecutive year at the Cell & Gene Meeting on the Mesa, the U.S.’s leading conference in the CGT industry
· Attended BioJapan, Asia’s largest bio-pharma event in Japan
· Discussed partnerships, licensing, and other business opportunities with global pharmaceutical and biotech companies

MEDIPOST (CEO Wonil Oh) recently participated in a global conference and a bio-pharma event in the U.S. and Japan, engaging in business discussions with numerous multinational pharmaceutical and biotech companies.

The Cell & Gene Meeting on the Mesa, which took place until the 9th of this month, is the premier annual conference in the cell and gene therapy (CGT) industry, organized by the Alliance for Regenerative Medicine (ARM). This year’s event took place in Arizona, U.S., where 124 companies showcased their achievements in clinical trials, gene editing, tissue engineering, and regenerative medicine technologies Participants held over 5,000 one-on-one meetings to discuss business development.

At the event, MEDIPOST’s Executive Director Antonio Seung Jin Lee, delivered a focused presentation on the excellence of CARTISTEM^® and its global clinical progress while also holding business meetings with multinational pharmaceutical companies, biotech firms, and potential partners. Antonio Seung Jin Lee, who holds a Ph.D. in biology, joined MEDIPOST in 2011 and has served as the Head of Business Development and Director of the U.S. Branch. He currently serves as the Global President of MEDIPOST Korea and CEO of the company’s U.S. and Japanese subsidiaries.

Additionally, MEDIPOST participated in BioJapan, Asia’s largest bio-pharma event, which ran until the 11th of this month. During the event, the company provided an update on the progress of CARTISTEM^®‘s Phase 3 trials in Japan and engaged in business discussions with global pharmaceutical and biotech companies, focusing on potential partnerships and licensing opportunities. BioJapan is a premier international bio-pharma event held annually in Yokohama, Japan, attracting around 1,500 global companies, including Novartis, Bayer, and Pfizer, and facilitating approximately 20,000 partnering meetings.

A MEDIPOST representative stated, “At these global conferences and bio-pharma events, we have explored various business opportunities, including partnerships and licensing opportunities, with leading pharmaceutical and biotech companies. With patient enrollment for the Phase 3 clinical trials in Japan nearing completion and preparations for the U.S. Phase 3 clinical trials progressing smoothly, we are committed to achieving successful partnership outcomes.”

MEDIPOST’s CARTISTEM^®, a treatment for knee osteoarthritis, received marketing approval from the Korea Ministry of Food and Drug Safety in 2012. The therapy has since been administered to over 30,000 patients, and the company is now focused on expanding its global reach, with ongoing Phase 3 clinical trials in Japan and preparations for Phase 3 clinical trials in the U.S.